Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort:a retrospective-prospective blinded study

Tytuł :
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort:a retrospective-prospective blinded study
Index Terms :
Adult
Aged
Biomarkers, Pharmacological
Breast Neoplasms/drug therapy
Disease Progression
Disease-Free Survival
Epirubicin/administration & dosage
Female
Gene Expression Regulation, Neoplastic/drug effects
Humans
Middle Aged
Neoplasm Proteins/genetics
Precision Medicine
Proportional Hazards Models
Prospective Studies
RNA, Messenger/genetics
Retrospective Studies
dk/atira/pure/researchoutput/pubmedpublicationtype/D016428
Journal Article
article
Wydawca :
2018
Dodane szczegóły :
Buhl, Anna Sofie Kappel
Christensen, Troels Dreier
Christensen, Ib Jarle
Nelausen, Knud Mejer
Balslev, Eva
Knoop, Ann Søegaard
Brix, Eva Harder
Svensson, Else
Glavicic, Vesna
Luczak, Adam
Langkjer, Sven Tyge
Linnet, Søren
Jakobsen, Erik Hugger
Bogovic, Jurij
Ejlertsen, Bent
Rasmussen, Annie
Hansen, Anker
Knudsen, Steen
Nielsen, Dorte
Jensen, Peter Buhl
Typ dokumentu :
Zasób elektroniczny
Dostępność :
Open access content. Open access content
info:eu-repo/semantics/openAccess
Pozostałe numery :
DAV oai:pure.atira.dk:publications/d94324d4-b6ee-484b-9f67-4ebcfeaf6560
https://curis.ku.dk/portal/da/publications/predicting-efficacy-of-epirubicin-by-a-multigene-assay-in-advanced-breast-cancer-within-a-danish-breast-cancer-cooperative-group-dbcg-cohort(d94324d4-b6ee-484b-9f67-4ebcfeaf6560).html
https://doi.org/10.1007/s10549-018-4918-4
https://curis.ku.dk/ws/files/222252352/Buhl2018_Article_PredictingEfficacyOfEpirubicin.pdf
1111911535
Źródło wspomagające :
UNIV OF COPENHAGEN
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
edsoai.on1111911535
Zasób elektroniczny
PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95% CI -0.93, one-sided). A 75% DRP was associated with a median TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies